SAN DIEGO / Mar 12, 2024 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.
Details regarding the Revelation fireside chat are as follows:
35th Annual Roth Conference Presentation Details
Date: | Monday, March 18, 2023 | |
Time: | 11:00 a.m. Pacific Time | |
Location: | The Ritz Carlton, Laguna Niguel, CA | |
Webcast: |
A live webcast of the presentation will also be available in the Investor Relations section of Revelation’s website at https://www.revbiosciences.com. A replay of the presentation will be available on Revelation’s website for 30 days following the event.
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including GEMINI-SSI as a prevention for post-surgical infection, GEMINI-AKI as a prevention for acute kidney injury, and GEMINI-CKD for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Last Trade: | US$0.58 |
Daily Change: | -0.03 -5.18 |
Daily Volume: | 439,786 |
Market Cap: | US$4.850M |
December 03, 2024 December 02, 2024 November 12, 2024 November 08, 2024 September 24, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load